EyePoint reports topline results from second pivotal Phase 3 DURAVYU trial
EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU in wet AMD.
Story updates
11:07:52 AM UTC
SquawkNews
LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement —— Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.00…
11:08:22 AM UTC
SquawkNews
EyePoint reported topline data from LUCIA: DURAVYU did not meet the primary non-inferiority BCVA endpoint vs on—label aflibercept, though key secondary endpoints were met, including a 38% reduction in treatment burden and favorable safety. DME Phase 3 topline is expected in Q4 2027.Material Details…
11:13:23 AM UTC
SquawkNews
EyePoint announced LUCIA topline: DURAVYU showed visual improvement but did not meet non—inferiority for mean BCVA versus on—label aflibercept.Key Highlights:Original SEC Filing: EyePoint, Inc. [ EYPT ] - 8-K - Oct. 19, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verify…
11:24:03 AM UTC
SquawkNews
EyePoint will reduce its workforce by approximately 53% and end Phase 3 wet AMD trials early after LUCIA failed non-inferiority. The company will prioritize DURAVYU in DME, with Phase 3 topline data expected in Q4 2027; cash was ~$118M on Sept. 30, 2026.Material DetailsContext by AI AnalystThis is…